Literature DB >> 18461672

Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells.

Gui-li Wang1, Ze-qing Wen, Wan-peng Xu, Zhi-yu Wang, Xue-lian Du, Fei Wang.   

Abstract

AIM: To explore the role of lysophosphatidic acid receptor-2 (LPA2) in regulating lysophosphatidic acid (LPA)-induced urokinase plasminogen activator (uPA) activation, cell invasion, and migration in human ovarian cancer cell line SKOV-3.
METHODS: SKOV-3 cells were stimulated with LPA. Cell supernatant uPA level and activity were measured using enzyme-linked immunosorbent assay. LPA2 mRNA expression was inhibited with LPA2-specific small interfering RNA (siRNA) and examined using semiquantitative reverse transcriptase-polymerase chain reaction. LPA-induced cell invasion and migration in transfected cells were evaluated by a Matrigel invasion chamber and a Transwell chemotaxis chamber, respectively.
RESULTS: LPA stimulation significantly enhanced in vitro uPA activity in time- and dose-dependent manner. The levels of LPA-induced uPA protein decreased by 55% in LPA2 siRNA-transfected cells compared with negatively transfected cells at 24 hours after being treated with 80 micromol/L LPA (0.75+/-0.03 vs 0.34+/-0.04, P=0.004). In the LPA2 specific siRNA-transfected SKOV-3 cells, LPA treatment at 80 micromol/L induced considerably less invasion and migration compared with negative control siRNA-transfected SKOV-3 cells (invasion: 178+/-17.2 vs 36.2+/-3.3, P=0.009; migration: 220.4+/-25.5 vs 57+/-7.6, P=0.009).
CONCLUSION: LPA2 has an essential role in LPA-induced uPA activation and tumor cell invasion in ovarian cancer SKOV-3 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461672      PMCID: PMC2359884          DOI: 10.3325/cmj.2008.2.175

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  21 in total

1.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.

Authors:  Y L Hu; M K Tee; E J Goetzl; N Auersperg; G B Mills; N Ferrara; R B Jaffe
Journal:  J Natl Cancer Inst       Date:  2001-05-16       Impact factor: 13.506

2.  Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1.

Authors:  Dai Shida; Joji Kitayama; Hironori Yamaguchi; Yurai Okaji; Nelson Hirokazu Tsuno; Toshiaki Watanabe; Yoh Takuwa; Hirokazu Nagawa
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Authors:  T B Pustilnik; V Estrella; J R Wiener; M Mao; A Eder; M A Watt; R C Bast; G B Mills
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

4.  Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions.

Authors:  W Siess; K J Zangl; M Essler; M Bauer; R Brandl; C Corrinth; R Bittman; G Tigyi; M Aepfelbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

5.  Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer.

Authors:  K M Schulte; A Beyer; K Köhrer; S Oberhäuser; H D Röher
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

Review 6.  Lysophosphatidic acid as a novel cell survival/apoptotic factor.

Authors:  Xiaoqin Ye; Isao Ishii; Marcy A Kingsbury; Jerold Chun
Journal:  Biochim Biophys Acta       Date:  2002-12-30

7.  Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family.

Authors:  Kyoko Noguchi; Satoshi Ishii; Takao Shimizu
Journal:  J Biol Chem       Date:  2003-04-30       Impact factor: 5.157

8.  Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.

Authors:  Yu-Long Hu; Chris Albanese; Richard G Pestell; Robert B Jaffe
Journal:  J Natl Cancer Inst       Date:  2003-05-21       Impact factor: 13.506

Review 9.  Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Authors:  Xianjun Fang; Michel Schummer; Muling Mao; Shuangxing Yu; Fazal Haq Tabassam; Ramona Swaby; Yutaka Hasegawa; Janos L Tanyi; Ruthie LaPushin; Astrid Eder; Robert Jaffe; Jim Erickson; Gordon B Mills
Journal:  Biochim Biophys Acta       Date:  2002-05-23

10.  Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.

Authors:  Thomas M McIntyre; Aaron V Pontsler; Adriana R Silva; Andy St Hilaire; Yong Xu; Jerald C Hinshaw; Guy A Zimmerman; Kotaro Hama; Junken Aoki; Hiroyuki Arai; Glenn D Prestwich
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-26       Impact factor: 11.205

View more
  7 in total

Review 1.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

Review 2.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

3.  Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma.

Authors:  Jinge Si; Yuanyuan Su; Yifeng Wang; You-Liang Yan; Ya-Ling Tang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 4.  LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Authors:  Yun C Yung; Nicole C Stoddard; Jerold Chun
Journal:  J Lipid Res       Date:  2014-03-18       Impact factor: 5.922

Review 5.  Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2018-07-09       Impact factor: 6.639

6.  Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways.

Authors:  Hadil Onallah; Ben Davidson; Reuven Reich
Journal:  J Oncol       Date:  2019-09-17       Impact factor: 4.375

7.  Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer.

Authors:  Carmen E Pyragius; Maria Fuller; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2013-04-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.